Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927729 | 1.00 | NFKB1 (0.35) | NFKB1NFKB2RELAPOLBHPGD | |
| SCHEMBL10890002 | 0.71 | TSHR (0.39) | POLBHPGDSMN1; SMN2TSHR | |
| SCHEMBL19927772 | 0.69 | MEN1 (0.33) | NFKB1NFKB2RELAPOLBTSHR | |
| SCHEMBL19927773 | 0.69 | MEN1 (0.33) | NFKB1NFKB2RELAPOLBTSHR | |
| SCHEMBL19968799 | 0.69 | MEN1 (0.33) | NFKB1NFKB2RELAPOLBTSHR | |
| SCHEMBL5718172 | 0.67 | MEN1 (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL6785191 | 0.67 | MEN1 (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL18179521 | 0.67 | TSHR (0.37) | POLBHPGDSMN1; SMN2TSHR | |
| SCHEMBL12994212 | 0.66 | ALDH1A1 (0.42) | NFKB1NFKB2RELAHPGDSMN1; SMN2 | |
| SCHEMBL9252549 | 0.65 | NFKB1 (0.36) | NFKB1NFKB2RELAPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | NFKB1 1236/4885NFKB2 1404/4885RELA 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.